NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Eldorado Resorts, Inc. ("Eldorado" or the "Company") (NASDAQ:ERI) and certain of its officers, on behalf of shareholders who purchased Eldorado securities between March 1, 2019 and September 2, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/eri.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) several of the Company's executive officers, including CEO Thomas Reeg, engaged in improper trading with respect to the securities of another publicly-traded company; and (2) as a result, Defendants' statements about Eldorado's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/eri or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Eldorado you have until November 22, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560862

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Slack Technologies, Inc. ("Slack" or "the Company") (NYSE:WORK) and certain of its officers, on behalf of shareholders who purchased Slack securities pursuant or traceable to Slack's initial public offering of ordinary shares conducted in June 2019 (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/work.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company's Slack Platform was susceptible to recurring service-level disruptions; (2) such disruptions were increasingly likely to occur as the Company scaled its services to a larger user base; (3) the Company provides credits even if a customer was not specifically affected by service-level disruptions; (4) as a result, any service-level disruptions would have a material adverse impact on the Company's financial results; and (4) as a result, Slack's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/work or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Slack you have until November 18, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560848

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ProPetro Holdings Corp.("ProPetro" or "the Company") (NYSE:PUMP) and certain of its officers, on behalf of shareholders who purchased ProPetro securities pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's March 2017initial public offering ("IPO or the "Offering"); and/or between March 17, 2017and August 8, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site:www.bgandg.com/pump.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company's executive officers were improperly reimbursed for certain expenses; (2) the Company had engaged in certain undisclosed transactions with related parties; (3) the Company lacked adequate disclosure controls and procedures; (4) the Company lacked effective internal control over financial reporting; and (5) as a result, ProPetrol's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/pump or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a lossin ProPetroyou have until November 15, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560733

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Nektar Therapeutics (NASDAQ:NKTR)

Class Period: February 15, 2019 – August 8, 2019

Deadline: October 18, 2019
For more info:www.bgandg.com/nktr

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that the Company did not comply with current good manufacturing practices; (2) that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (3) that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; (4) that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit; and (5) as a result, Nektar's public statements were materially false and misleading at all relevant times.

Pluralsight, Inc. (NASDAQ:PS)

Class Period: August 2, 2018 – July 31, 2019

Deadline: October 15, 2019
For more info:www.bgandg.com/ps

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Pluralsight was experiencing sales execution challenges which impacted its billings; (2) Pluralsight was experiencing substantial delays in hiring and properly training its salesforce that would be necessary to meet its lofty billing projections; (3) Pluralsight was behind on the onboarding of new sales representatives which was causing sales execution issues and preventing the Company from meeting its high growth projections; and (4) as a result, Pluralsight's public statements were materially false and misleading at all relevant times.

Burford Capital Limited (OTCPINK: BRFRF, BRFRY)
Class Period: March 18, 2015 – August 7, 2019

Deadline: October 21, 2019
For more info:www.bgandg.com/brfrf

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Burford has been manipulating its metrics, including ROIC and IRR, to create a misleading picture of investment returns to investors; (2) these manipulations hid the fact that the Company is at high risk for a liquidity crunch and is already arguably insolvent; and (3) as a result of the aforementioned misconduct, Defendants' statements about Burford's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560604

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sundial Growers Inc. ("Sundial" or the "Company") (NASDAQ:SNDL) and certain of its officers, on behalf of shareholders who purchased Sundial securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Registration Statement") issued in connection with Sundial's August 1, 2019 initial public stock offering (the "IPO" or the "Offering"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/sndl.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Federal Securities Laws of 1933.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Sundial failed to supply saleable cannabis in line with contractual obligations to Zenabis Global Inc.; (2) due to material quality issues, Zenabis had to return or reject a total of 554 kg of cannabis to Sundial, valued at approximately U.S. $1.9 million (C$2.5 million); and (3) as a result, defendants' statements about Sundial's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/sndl or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Sundial you have until November 25, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 561151

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ:MGNX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Macro Genics securities between February 6, 2019 and June 3, 2019,both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/mgnx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (2) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (3) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late; and (4) as a result, MacroGenic's public statements were materially false and misleading at all relevant times.

On May 13, 2019, the American Society of Clinical Oncologists ("ASCO") posted online the abstract of MacroGenics' Phase III SOPHIA study of the Company's margetuximab product, which disclosed that the October 2018 progression-free survival ("PFS") analysis resulted in a 0.9 month improvement in PFS. On this news, MacroGenics' stock price fell $1.17 per share, or 6.72%, to close at $16.25 per share on May 13, 2019. Then, on June 4, 2019, during the ASCO annual meeting in Chicago, Illinois, MacroGenics disclosed additional data for the SOPHIA trial. MacroGenics' presentation revealed to the public that the Company had conducted its PFS and overall survival ("OS") analyses in October 2018, and that the OS analyses for the SOPHIA trial did not reflect encouraging post-treatment survival statistics for patients. On this news, Macrogenics' stock price fell $3.13 per share, or 16.73%, to close at $15.58 per share on June 4, 2019.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/mgnx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in MacroGenics you have until November 12, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560671

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Abiomed, Inc. (NASDAQ:ABMD)
Class Period: January 31, 2019 – July 31, 2019
Deadline: October 7, 2019
For more info: www.bgandg.com/abmd

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) ABIOMED's revenue growth was in decline; (2) the Company did not have a sufficient plan in place to stem its declining revenue growth; (3) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (4) consequently, ABIOMED was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times.

International Flavors & Fragrances Inc. (NYSE:IFF)
Class Period: May 7, 2018 – August 5, 2019
Deadline: October 11, 2019
For more info: www.bgandg.com/iff

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that Frutarom had bribed customers in Russia and Ukraine; (2) that senior management at Frutarom were aware of such improper payments; (3) that, as a result, Frutarom's financial results were materially overstated; (4) that, as a result of the improper payments, the Company was reasonably likely to face regulatory scrutiny; (5) that the Company had not completed adequate due diligence before acquiring Frutarom; (6) that, as a result of the foregoing, the Company was unlikely to achieve purported synergies from the acquisition; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Granite Construction Incorporated (NYSE:GVA)
Class Period: October 26, 2018 – August 1, 2019
Deadline: October 15, 2019
For more info:www.bgandg.com/gva

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company had assumed certain risks in connection with its heavy civil joint venture projects bid between 2012 and 2014; (2) there was an "untenable" imbalance of risk sharing between the Company and the joint venture project owners; (3) the Company was reasonably likely to incur additional project costs for its joint venture projects; (4) the Company was reasonably likely to incur additional costs in connection with certain project disputes; and (5) as a result, Granite Construction's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 |info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560585

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Meredith Corporation (NYSE:MDP)

Class Period: May 10, 2018 – September 4, 2019

Deadline: November 5, 2019
For more info:www.bgandg.com/mdp

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Time, Inc. acquisition was not as profitable as Meredith had claimed; (2) Meredith would incur additional costs for strategic investments to improve the Time business; (3) Meredith's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, defendants' positive statements about Meredith's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

MINDBODY, Inc.(NASDAQ:MB)

Class Period: November 7, 2018 – February 15, 2019

Deadline: November 4, 2019
For more info:www.bgandg.com/mb

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Defendants had put scheme in place to depress the value of MINDBODY stock directly preceding the merger offer by Vista manufactured through the negative guidance issued on November 6, 2018; (2) the "goshop" provision in the merger offer was designed to prevent any superior offers by other potential purchasers; (3) at the behest of Vista, Defendants never released the Company's favorable fourth quarter 2018 results; (4) as a result of the following, the merger consideration was not fair, and any fairness opinions rendered by the independent proxy advisory firms were based off of incomplete information. Thus, MINDBODY shareholders were not paid the fair value of their shares in connection with the merger, and suffered harm as a result of this alleged conduct in violation of the federal securities laws.

Cadence Bancorporation (NYSE:CADE)

Class Period: July 23, 2018 – July 22, 2019

Deadline: November 15, 2019
For more info:www.bgandg.com/cade

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) that the company lacked adequate internal controls to assess credit risk; (2) that, as a result, certain of the company's loans posed an increased risk of loss; (3) that, as a result, the company was reasonably likely to incur significant losses for certain loans; (4) that the company's financial results would suffer a material adverse impact; and (5) that, as a result of the foregoing, defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560623

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

CVS Health Corporation (NYSE:CVS)

Class Period: shareholders who acquired CVS shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018

Deadline: October 14, 2019
For more info:www.bgandg.com/cvs

In connection with the acquisition of Aetna (the "Acquisition"), defendants filed with the SEC a Registration Statement on Form S-4, which was declared effective on February 9, 2018, and a joint proxy statement/prospectus on Form 424B3 (collectively the "Offering Documents"). The complaint alleges that the Offering Documents contained materially false and/or misleading statements about CVS's compliance with Generally Accepted Accounting Principles ("GAAP"). Specifically, CVS misrepresented in the Offering Documents that it had properly accounted for its $6+ billion goodwill asset, as reported in the "LTC unit," associated with CVS's 2015 acquisition of LTC pharmacies of Omnicare.

NetApp, Inc. (NASDAQ:NTAP)

Class Period: May 22, 2019- August 1, 2019

Deadline: October 15, 2019
For more info:www.bgandg.com/ntap

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company was unable to close large deals within the quarter and that the deals were pushed out to subsequent quarters or downsized; (2) the Company's revenue would be materially impacted; (3) the Company would lower its fiscal 2020 guidance; and (4) as a result, NetApp's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

SAExploration Holdings, Inc. (NASDAQ:SAEX)
Class Period: March 15, 2016 – August 15, 2019

Deadline: October 17, 2019
For more info:www.bgandg.com/saex

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the existence of SEC and internal investigations into the Company's financial reporting; (2) the need for SAEX to restate all of its financial statements covering 2015 through 2018; (3) CEO Jeffrey Hastings had been placed on administrative leave; and (4) CFO and General Counsel Brent Whitely had been fired.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560596

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ollie's Bargain Outlet Holdings, Inc. ("Ollie's" or "the Company") (NASDAQ:OLLI) and certain of its officers, on behalf of shareholders who purchased Ollie's securities between June 6, 2019 and August 28, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/olli.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company suffered a supply chain issue that impacted the initial inventory available at new stores; (2) as a result, the Company lacked sufficient inventory to meet demand at certain store locations; (3) as a result, the Company's comparable store sales were likely to decrease quarter-over-quarter; and (4) as a result, Ollie's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/olli or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Ollie's you have until November 18, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 560842